The PI3K inhibitor arsenal: choose your weapon!

Trends in Biochemical Sciences

Volumn 32, Issue 10, 2007, Pages 450-456

  Crabbe, Tom ^a   Welham, Melanie J ^b   Ward, Stephen G ^b  

^a UCB PHARMA   (Belgium)

^b University of Bath   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ADENOSINE TRIPHOSPHATE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CYTOKINE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; G PROTEIN COUPLED RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; GROWTH FACTOR; IC 187114; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PI 103; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE PIM 1; PROTEIN KINASE PIM 2; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; STAT PROTEIN; TG 100115; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZSTK 474;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; DRUG ACTIVITY; DRUG RESEARCH; DRUG SELECTIVITY; ENZYME INHIBITION; HUMAN; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ENZYME ACTIVATION; INFLAMMATION; NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 35348926002     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2007.09.001     Document Type: Review

References (65)

1. Whitman M., et al. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 332 (1988) 644-646
2. Courtneidge S.A., and Heber A. An 81 kd protein complexed with middle T antigen and pp60c-src: a possible phosphatidylinositol kinase. Cell 50 (1987) 1031-1037
3. Ruckle T., et al. PI3Kγ inhibition: towards an 'aspirin of the 21st century'?. Nat Rev Drug Discov 5 (2006) 903-918
4. Rommel C., et al. PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond?. Nat. Rev. Immunol. 7 (2007) 191-201
5. Hennessy B.T., et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4 (2005) 988-1004
6. Engelman J.A., et al. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7 (2006) 606-619
7. Vanhaesebroeck B., et al. Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem. Sci. 30 (2005) 194-204
8. Jackson S.P., et al. PI 3-kinase p110β: a new target for antithrombotic therapy. Nat. Med. 11 (2005) 507-514
9. Rodriguez-Viciana P., et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370 (1994) 527-532
10. Vanhaesebroeck B., et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu. Rev. Biochem. 70 (2001) 535-602
11. Samuels Y., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
12. Vogt P.K., et al. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem. Sci. 32 (2007) 342-349
13. Karakas B., et al. Mutation of the PIK3CA oncogene in human cancers. Br. J. Cancer 94 (2006) 455-459
14. Ward S.G., and Cantrell D.A. Phosphoinositide 3-kinases in T lymphocyte activation. Curr. Opin. Immunol. 13 (2001) 332-338
15. Deane J.A., and Fruman D.A. Phosphoinositide 3-kinase: diverse roles in immune cell activation. Annu. Rev. Immunol. 22 (2004) 563-598
16. Okkenhaug K., et al. Antigen receptor signalling: a distinctive role for the p110delta isoform of PI3K. Trends Immunol. 28 (2007) 80-87
17. Hirsch E., et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 287 (2000) 1049-1053
18. Li Z., et al. Roles of PLC-β2 and -β3 and PI3Kγ in chemoattractant-mediated signal transduction. Science 287 (2000) 1046-1049
19. Sasaki T., et al. Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration. Science 287 (2000) 1040-1046
20. Ali K., et al. Essential role for the p110δ phosphoinositide 3-kinase in the allergic response. Nature 431 (2004) 1007-1011
21. Thomas M.J., et al. Airway inflammation: chemokine-induced neutrophilia and the class I phosphoinositide 3-kinases. Eur. J. Immunol. 35 (2005) 1283-1291
22. Laffargue M., et al. Phosphoinositide 3-kinaseγ is an essential amplifier of mast cell function. Immunity 16 (2002) 441-451
23. Condliffe A.M., et al. Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106 (2005) 1432-1440
24. Webb L.M., et al. Cutting Edge: T cell development requires the combined activities of the p110γ and p110δ catalytic isoforms of phosphatidylinositol 3-kinase. J. Immunol. 175 (2005) 2783-2787
25. Wiesinger D., et al. Anti-inflammatory activity of the new mould metabolite 11-desacetoxy-wortmannin and of some of its derivatives. Experientia 30 (1974) 135-136
26. Baggiolini M., et al. Inhibition of the phagocytosis-induced respiratory burst by the fungal metabolite wortmannin and some analogues. Exp. Cell Res. 169 (1987) 408-418
27. Arcaro A., and Wymann M.P. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem. J. 296 (1993) 297-301
28. Wymann M.P., et al. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol. Cell. Biol. 16 (1996) 1722-1733
29. Vlahos C.J., et al. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269 (1994) 5241-5248
30. Gharbi S.I., et al. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem. J. 15 (2007) 15-21
31. Ward S.G., and Finan P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr. Opin. Pharmacol. 3 (2003) 426-434
32. Walker E.H., et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell 6 (2000) 909-919
33. Sadhu C., et al. Essential role of phosphoinositide 3-kinase-δ in neutrophil directional movement. J. Immunol. 170 (2003) 2647-2654
34. Knight Z.A., et al. A pharmacological map of the PI3K family defines a role for p110α in insulin signalling. Cell 125 (2006) 733-747
35. Doukas J., et al. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 19866-19871
36. Firestein G.S. Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. J. Clin. Invest. 103 (1999) 3-4
37. Yaguchi S., et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J. Natl. Cancer Inst. 98 (2006) 545-556
38. Tamura N., et al. Anti-rheumatic effect of ZSTK474, a novel phosphoinositide 3-kinase inhibitor. Arthritis Rheum. 54 (2006) S413
39. Hayakawa M., et al. Synthesis and biological evaluation of pyrido[3′,2′:4,5]furo[3,2-d]pyrimidine derivatives as novel PI3K p110α inhibitors. Bioorg. Med. Chem. Lett. 17 (2007) 2438-2442
40. Fan Q.W., et al. A dual PI3K/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9 (2006) 341-349
41. Sun S.Y., et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65 (2005) 7052-7058
42. Jacobs M.D., et al. Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002. J. Biol. Chem. 280 (2005) 13728-13734
43. Fox C.J., et al. The Pim kinases control rapamycin-resistant T cell survival and activation. J. Exp. Med. 201 (2005) 259-266
44. Cibull T.L., et al. Overexpression of Pim-1 during progression of prostatic adenocarcinoma. J. Clin. Pathol. 59 (2006) 285-288
45. Cheney I.W., et al. Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase. Bioorg. Med. Chem. Lett. 17 (2007) 1679-1683
46. Foukas L.C., et al. Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441 (2006) 366-370
47. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22 (2004) 531-562
48. Coombes J.L., et al. Regulatory T cells and intestinal homeostasis. Immunol. Rev. 204 (2005) 184-194
49. Okkenhaug K., et al. The p110δ isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. J. Immunol. 177 (2006) 5122-5128
50. Patton D.T., et al. The phosphoinositide 3-kinase p110δ is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol. 177 (2006) 6598-6602
51. Okkenhaug K., et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297 (2002) 1031-1034
52. Fukao T., and Koyasu S. PI3K and negative regulation of TLR signaling. Trends Immunol. 24 (2003) 358-363
53. Fukao T., et al. Selective loss of gastrointestinal mast cells and impaired immunity in PI3K-deficient mice. Nat. Immunol. 3 (2002) 295-304
54. Fukao T., et al. PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat. Immunol. 3 (2002) 875-881
55. Yilmaz O.H., et al. PTEN dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441 (2006) 475-482
56. Zhang J., et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441 (2006) 518-522
57. Collis S.J., et al. The life and death of DNA-PK. Oncogene 24 (2005) 949-961
58. Burma S., and Chen D.J. Role of DNA-PK in the cellular response to DNA double-strand breaks. DNA Repair (Amst.) 3 (2004) 909-918
59. Goozner M. Excerpt from the $800 million pill - me too!. MedGenMed 6 (2004) 57
60. Ward S.G. Do phosphoinositide 3-kinases direct lymphocyte navigation?. Trends Immunol. 25 (2004) 67-74
61. Suire S., et al. p84, a new Gβγ-activated regulatory subunit of the type IB phosphoinositide 3-kinase p110gamma. Curr. Biol. 15 (2005) 566-570
62. Voigt P., et al. Characterization of p87PIKAP, a novel regulatory subunit of phosphoinositide 3-kinase gamma that is highly expressed in heart and interacts with PDE3B. J. Biol. Chem. 281 (2006) 9977-9986
63. 3- and Gβγ-regulated guanine-nucleotide exchange factor for Rac. Cell 108 (2002) 809-821
64. Shinohara M., et al. SWAP-70 is a guanine-nucleotide-exchange factor that mediates signalling of membrane ruffling. Nature 416 (2002) 759-763
65. Ward S.G. T lymphocytes on the move: chemokines, PI 3-kinase and beyond. Trends Immunol. 27 (2006) 80-87